A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD)

The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.

开始日期2024-05-10

申办/合作机构

Cybin IRL Ltd.

[+1]

CTIS2023-507409-32-00

/ Not yet recruiting临床1期

A study to investigate the safety, pharmacodynamics and pharmacokinetics of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjects

开始日期2023-12-04

申办/合作机构

Cybin IRL Ltd.

100 项与 Deuterated dtryptamine 相关的临床结果

登录后查看更多信息

100 项与 Deuterated dtryptamine 相关的转化医学

登录后查看更多信息

100 项与 Deuterated dtryptamine 相关的专利（医药）

登录后查看更多信息

项与 Deuterated dtryptamine 相关的文献（医药）

2024-02-01·European heart journal. Case reports

Hybrid endovascular treatment for complicated aortic dissection concomitant with true lumen obliteration: a case report

作者: Ikeoka, Kuniyasu ; Ueda, Yasunori ; Nishi, Hiroyuki ; Yamane, Haruya ; Matsumura, Yasushi

Abstract:

Background:

Thoracic endovascular aortic repair (TEVAR) has been widely introduced. However, unestablished transfemoral approach due to true lumen obliteration disables endovascular option.

Case summary:

A 74-year-old male with a history of 15-year-ago type B aortic dissection presented with chronic bilateral lower extremity claudication. CT angiography revealed that a large entry tear was located at distal to the left subclavian artery. The thoracic aneurysmal degeneration progressed and eventually required repair. True lumen of infrarenal aorta to bilateral common iliac arteries was totally collapsed by false lumen, and the re-entry tear was open at external iliac artery. Initially, we performed recanalization to the collapsed true lumen. Bidirectional approach was taken from right brachial and bifemoral arteries. The covered endovascular reconstruction of aortic bifurcation (CERAB) technique and double D-shape moulding technique (DDMT) was performed to create covered stent configuration. As secondary treatment, 1-debranching TEVAR with axillary artery bypass was successfully performed by utilizing femoral approach.

Discussion:

This case demonstrated feasibility of two-stage endovascular therapy for thoracic aneurysmal degeneration concomitant with true lumen obliteration. This combined technique of CERAB and DDMT was absolutely effective to minimize type Ⅲ endoleak in infrarenal segment. Hybrid endovascular treatment offered minimally invasive therapy to the patient.

JOURNAL OF PSYCHOPHARMACOLOGY

Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated N,N -dimethyltryptamine (CYB004) in healthy volunteers

Article

作者: de Kam, Marieke L. ; Otto, Marije E. ; Jacobs, Gabriel E. ; James, Ellen H. ; van Gerven, Joop M. A. ; van der Heijden, Katelijne V. ; Bohoslavsky, Roman ; Nathan, Pradeep J. ; Inamdar, Amir

Background::

Serotonergic psychedelics, such as N,N -dimethyltryptamine (DMT), have shown therapeutic potential in various psychiatric disorders. However, DMT demonstrates pharmacokinetic (PK) variability and a short half-life.

Aims::

This exploratory study investigated the PK, pharmacodynamic (PD), and safety profile of CYB004, a deuterated DMT analogue, following intravenous administration in healthy volunteers.

Methods::

CYB004, a deuterated DMT analogue, was evaluated in a randomized, double-blind, placebo-controlled, two-part study in healthy participants. Part 1 was a single-dose cohort, in which participants received a 5-minute intravenous 12.7 mg CYB004 bolus, followed by a 30-minute 15.41 mg infusion. Part 2 was a three-way crossover, during which two separate 5-minute 12.7 mg CYB004 boluses were administered. Outcome measures included PK of CYB004 and subjective, autonomic, neurophysiological, and adverse effects.

Results::

Although high CYB004 doses led to intense psychedelic experiences and participant withdrawals, lower doses achieving plasma concentrations similar to those in previous DMT studies demonstrated an acceptable safety profile. CYB004 demonstrated a PD profile that was similar to DMT at comparable plasma concentrations. PD effects consisted of subjective psychedelic effects, electroencephalography power band reductions, and autonomic nervous system activation. CYB004’s half-life was approximately two-fold longer than DMT, prolonging the duration of psychedelic effects to ~40–60 minutes following brief intravenous administration. However, deuteration did not improve PK variability, with IV-administered CYB004 demonstrating moderate to high variability, largely driven by interindividual differences.

Conclusion::

CYB004 demonstrated PD effects comparable to DMT. However, CYB004 demonstrated an extended duration of these effects due to reduced clearance, while maintaining an acceptable safety profile at clinically relevant exposures despite PK variability.

Environmental science and pollution research international

Laboratory investigations of the conservativeness of deuterated water as the artificial tracer for hydrogeological tests

Article

作者: Mei, Jie ; Liu, Guodong ; Huang, Xiaohua ; Chen, Yu

Deuterated water has been applied in hydrogeological tracer tests in recent years. However, there is a contradiction in the conservativeness of the artificial deuterium (D/²H). In this study, what circumstances HDO behaved truly conservatively were investigated through the laboratory-scale sand tank by comparing with the widely used tracer chloride (Cl^-). In addition, the advection-dispersion equation (ADE) and dual-domain mass transfer (DDMT) equation were employed to describe the breakthrough curves (BTCs) of tracers. Reasons for the non-conservativeness of HDO were discussed comprehensively for the first time. HDO behaved conservatively when transported in the porous media with high permeability, and ADE could describe BTCs successfully. While HDO presented the phenomenon of retardation in media with low permeability, especially in the clay medium. DDMT was more suitable for demonstrating delayed BTCs. Hydrogen bonds between HDO and H₂O, the isotopic exchange effect, and the dual-domain of the media were used to explain the retardation of HDO. The retardation factor (R = 1.27) was used to describe transporting behaviors of HDO in clay first. The relatively large molecular coefficient of HDO could make the proportion of immobile regions of HDO greater than that of Cl^-. Tracers tend to be delayed when transported in the media with the larger porosity, smaller hydraulic gradient, and lower permeability. This work provides more considerations for using deuterium as artificial tracers in hydrogeological tests.

142

项与 Deuterated dtryptamine 相关的新闻（医药）

2026-10-01

·GlobeNewswire-Health Care

Helus Pharma Announces Completion of Legal Name Change

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company’s annual and special meeting of shareholders held on September 22, 2026. The name change follows the Company’s adoption of the business name “Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company. The Company’s common shares will continue to trade on the Nasdaq Global Market and Cboe Canada under the ticker symbol “HELP”. No action is required by existing shareholders, and outstanding share certificates and DRS statements remain valid. The new CUSIP number assigned to the Company’s common shares is 423492107 and its new ISIN is CA4234921076. The Company will continue to file documents under its updated profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. About Helus Pharma Helus Pharma Inc. is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to transform from a clinical stage discovery and development company to a commercial-ready pharmaceutical company; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026 and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. The Company makes no medical, treatment or health benefit claims about Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Company’s performance and operations. Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.‍Investor Contact:Matthew Beckastr partnersManaging Partner(917) 415-1750Matthew.beck@astrpartners.com Gabriel FahelChief Legal OfficerHelus Pharma1-866-292-4601irteam@helus.com – or – media@helus.com Media Contact:Victoria VerdejaRXMDPublic Relations Director(212) 537-9495vverdeja@rxmedyn.com

临床3期临床2期突破性疗法

2026-09-21

·BioSpace

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Poster presentations further characterize clinical pro HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. Three of the poster presentations build on findings from Helus Pharma’s completed Phase 1/2a randomized, double-blind study of HLP003 as a potential adjunctive therapy in participants with MDD. Data presented includes 12-month efficacy results. A trial-in-progress overview of PARADIGM, the ongoing Phase 3 clinical program of HLP003 was also presented. Poster #1 Title: Effects of HLP003 on MADRS Individual Items and Anhedonia Subscale in Adults With Major Depressive Disorder: Post Hoc Analysis of a Phase 1/2a Study Authors : Atul R. Mahableshwarkar, MD; Ken Kramer, PhD; Alexandra Kulikova, PhD; Amir Inamdar, MBBS, DNB (Psych), MFPM Poster Number: 124 Poster #2 Title: Understanding and Assessing the Psychedelic Experience From a Phase 1/2a Study of the Deuterated Psilocin Analog HLP003 in Adults With Major Depressive Disorder Authors: Atul R. Mahableshwarkar, MD; Sunita Shinde, MD; Ken Kramer, PhD; Alexandra Kulikova, PhD; Amir Inamdar, MBBS, DNB (Psych), MFPM Poster Number: 123 Poster #3 Title: Expanded Safety Analysis of the Deuterated Psilocin Analog HLP003 From a Phase 1/2a Study of Adult Participants With Major Depressive Disorder Authors: Sunita Shinde, MD; Alexandra Kulikova, PhD; Atul Mahableshwarkar, MD; Ken Kramer, PhD; Amir Inamdar, MBBS, DNB (Psych), MFPM Poster Number: 122 Poster #4 Title: A Phase 3 Clinical Program Evaluating the Efficacy and Safety of the Deuterated Psilocin Analog HLP003 as an Adjunctive Treatment for Major Depressive Disorder (PARADIGM) Authors: Amir Inamdar, MBBS, DNB (Psych), MFPM; Annette Massa, PharmD; Ken Kramer, PhD; Heather Prichard, PhD; Sunita Shinde, MD; Atul Mahableshwarkar, MD Poster Number: 121 About Helus Pharma Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding HLP003 as a potential adjunctive treatment for MDD; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company's pro SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations. Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. Investor Contact: Matthew Beck astr partners Managing Partner (917) 415-1750 Matthew.beck@astrpartners.com Gabriel Fahel Chief Legal Officer Helus Pharma 1-866-292-4601 irteam@helus.com – or – media@helus.com Media Contact: Victoria Verdeja RXMD Public Relations Director (212) 537-9495 vverdeja@rxmedyn.com

2026-09-21

·BioSpace

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually September 23, 2026. The fireside chat will be webcast live on Wednesday, September 23, 2026 at 9:00 a.m. EDT. To register for the webcast, click here . A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website. About Helus Pharma Helus Pharma, the commercial operating name of Cybin Inc. is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp. Cautionary Notes and Forward-Looking Statements Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s anticipated participation at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three months ended June 30, 2026, and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company's pro SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at . Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations. Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. Investor Contact: Matthew Beck astr partners Managing Partner (917) 415-1750 Matthew.beck@astrpartners.com Gabriel Fahel Chief Legal Officer Helus Pharma 1-866-292-4601 irteam@helus.com – or – media@helus.com Media Contact: Victoria Verdeja RXMD Public Relations Director (212) 537-9495 vverdeja@rxmedyn.com

100 项与 Deuterated dtryptamine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
广泛性焦虑障碍	临床2期	美国	Cybin IRL Ltd.	2024-05-10
抑郁症	临床1期	荷兰	Cybin IRL Ltd.	2023-12-04
焦虑症	临床1期	荷兰	Helus Pharma, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Company_Website 人工标引	临床2期	广泛性焦虑障碍	36	Placebo+Standard of Care	願願蓋蓋醖齋憲艱繭憲(壓積鬱鹹鬱廠築憲艱簾) = 願壓淵襯鬱選鑰憲餘製繭網壓遞窪構選鹹觸繭 (網願齋淵遞廠簾窪遞淵 )	积极	2026-03-05
				HLP004 20mg +Standard of Care	製衊築製鬱醖製蓋衊衊(餘壓衊憲鑰壓積鏇積觸) = 鏇餘憲構積膚選艱積鏇壓遞淵網蓋繭鹹選膚窪 (壓願鏇獵醖繭窪壓製蓋 ) 更多